Deals this week: Cynata Therapeutics, Sun Pharmaceutical Industries, Cardinal Health

8th September 2016 (Last Updated September 8th, 2016 18:30)

Cynata Therapeutics and Fujifilm Corporation have entered a term sheet for the development and commercialisation of a Cynata technology and its product CYP-001.

Cynata Therapeutics and Fujifilm Corporation have entered a term sheet for the development and commercialisation of a Cynata technology and its product CYP-001.

The partners will jointly finalise a definitive agreement by the fourth quarter of 2016, according to which, Fujifilm will invest up to $3m in Cynata by acquiring its shares, while Cyanta will provide Fujifilm an exclusive license to manufacture, market and sell its MSC products worldwide, along with certain rights to its technology.

The agreement also enables Cynata to receive certain upfront and milestone payments and royalty on end products.

Sun Pharmaceutical Industries (Sun Pharma) has entered a distribution agreement with Mitsubishi Tanabe Pharma Corporation to expand its sales in the Japanese pharmaceutical market, along with stable supply of medicines and healthcare information.

According to the agreement, Mitsubishi Tanabe Pharma will be responsible to market and distribute Sun Pharma’s 14 products and also provide their prescribing information to healthcare professionals.

The agreement enables Sun Pharma to expand its sales channel by transferring manufacturing and marketing rights of the 14 products.

Sanofi expects to raise gross proceeds of $1.28bn through a public offering of notes, due January 2027.

BNP Paribas SA and Morgan Stanley are acting as global co-ordinators and book runners for the offering, while Credit Agricole CIB S.A, Deutsche Bank AG, MUFG Americas Holdings Corporation and Natixis SA are acting as book runners.

The company plans to invest the funds for general corporate purposes.

Cardinal Health has announced that it has signed a letter of intent (LOI) with Navidea Biopharmaceuticals to acquire all rights to the latter’s Lymphoseek products of all FDA-approved, pending and future oncology diagnostic indications in North America.

"Sanofi expects to raise gross proceeds of $1.28bn through a public offering of notes, due January 2027."

According to the LoI, Cardinal Health will be responsible to make a total consideration of up to $310m for certain milestone and annual sales-based payments to Navidea Biopharmaceuticals.

Navidea will also receive a license to a portion of acquired intellectual property in order to develop, manufacture and market its new products and also license to market, manufacture and distribute Lymphoseek outside North America.

The agreement enables Cardinal Health to strengthen its product portfolio and will enable Navidea to repay its outstanding debts.

Sanofi has priced a public offering of its notes due in 2020 to raise $1.12bn. The company intends use the proceeds for general corporate purposes.


Image: BNP Paribas SA is acting as global co-ordinators and book runners for Sanofi's equity offering. Photo: courtesy of Tangopaso.